Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

Breast Cancer - Female Clinical Trial

Official title: Phase I Study of Pazopanib in Combination With Weekly Paclitaxel and Carboplatin to Assess the Safety and Tolerability in Patients With Advanced Solid Tumors

Status Terminated

Clinical Trial Summary

This is an open label, dose escalation study to determine the safety and tolerability and maximum tolerated dose of pazopanib combined with weekly paclitaxel and carboplatin in patients with advanced solid tumors.

Clinical Trial Description

This is an open label, dose escalation study to determine the maximum tolerated dose (MTD) of pazopanib combined with weekly paclitaxel and carboplatin in patients with advanced solid tumors. There will be a dose expansion cohort of thirty patients to assess detailed pharmacokinetics and to assess any signal of activity in patients with solid tumors and in a portion who have breast cancer that is triple negative (ER-negative, PR-negative, and HER2-negative). ;

Related Conditions & MeSH terms

• Breast Cancer - Female
• Neoplasms
• Unspecified Adult Solid Tumor - Protocol Specific

• NCT number: NCT01407562
• Study type: Interventional
• Source: Rutgers, The State University of New Jersey
• Status: Terminated
• Phase: Phase 1
• Start date: September 17, 2010
• Completion date: March 29, 2016